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Abstract
Aim: We measured meningococcal serogroup C (MenC)-specific memory B-cell responses in infants by Enzyme-Linked
Immunospot (ELISpot) following different MenC conjugate vaccine schedules to investigate the impact of priming on
immune memory.
Methods: Infants aged 2 months were randomised to receive 1 or 2 doses of MenC-CRM197 at 3 or 3 and 4 months, 1 dose
of MenC-TT at 3 months, or no primary MenC doses. All children received a Haemophilus influenzae type b (Hib)-MenC
booster at 12 months. Blood was drawn at 5, 12, 12 months +6 days and 13 months of age.
Results: Results were available for 110, 103, 76 and 44 children from each group respectively. Following primary
immunisations, and prior to the 12-month booster, there were no significant differences between 1- or 2-dose primed
children in the number of MenC memory B-cells detected. One month following the booster, children primed with 1 dose
MenC-TT had more memory B-cells than children primed with either 1-dose (p = 0.001) or 2-dose (p,0.0001) MenC-CRM197.
There were no differences in MenC memory B-cells detected in children who received 1 or 2 doses of MenC-CRM197 in
infancy and un-primed children.
Conclusions: MenC-specific memory B-cell production may be more dependent on the type of primary vaccine used than
the number of doses administered. Although the mechanistic differences between MenC-CRM197 and MenC-TT priming are
unclear, it is possible that structural differences, including the carrier proteins, may underlie differential interactions with B-
and T-cell populations, and thus different effects on various memory B-cell subsets. A MenC-TT/Hib-MenC-TT combination
for priming/boosting may offer an advantage in inducing more persistent antibody.
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Introduction
As a result of the sustained increase in serogroup C
meningococcal (MenC) disease in the United Kingdom (UK) in
the 1990’s, three MenC conjugate vaccines were licensed and
introduced into the routine infant immunisation schedule. These
included two different vaccines conjugated to a mutant diphtheria
toxoid (CRM197), and one conjugated to tetanus toxoid (TT).
MenC conjugate vaccines induce bactericidal polysaccharide-
specific antibodies, which have been shown to correlate with
protection against invasive disease [1,2,3]. In addition to inducing
immunological memory, as defined by an anamnestic antibody
response to subsequent challenge, several different factors are
thought to contribute to long-term protection after immunisation
with conjugate vaccines including reduced carriage, herd immu-
nity and persistence of bactericidal antibody in the serum [4,5].
In the UK, the currently available MenC-CRM197 and MenC-
TT conjugate vaccines are used interchangeably in the immuni-
sation schedule; however there is evidence that the TT-conjugated
vaccine is more immunogenic and in particular is a better
‘‘priming’’ vaccine irrespective of the type of booster vaccine that
is subsequently administered [6,7]. Furthermore, higher serum
bactericidal assay (SBA) titres were observed following Haemophilus
influenzae type b (Hib) and MenC conjugate (Hib-MenC-TT)
booster in children primed with Hib-MenC-TT than children
primed with monovalent MenC-CRM197 in the first year of life,
even though post-primary immunisation SBA titres were lower in
the former group [8,9]. These findings may relate to differences in
the ability of these vaccines to generate memory B-cells following
primary immunisations. It has been shown that antibody levels
following a MenC-TT booster at 12 months of age are higher in
children who received 1 dose of the same vaccine at 4 months of
age, compared to children who received 2 doses at 2 and 4 months
[10], and that infants primed with 1 dose of MenC-TT mounted a
greater antibody response to a polysaccharide challenge at 12
months of age, compared with those primed with either 2 or 3
doses of MenC-TT in infancy [11], suggesting that the number of
doses of primary vaccines may also be important in the generation
of memory B-cells.
Frequency of antigen-specific memory B-cells in peripheral
blood can be quantified by Enzyme-Linked Immunospot (ELI-
Spot) that detects immunoglobulin (Ig) G antibody secreting cells
(ASCs). As part of a larger study, we investigated MenC-specific
memory B-cells following different MenC conjugate vaccine
schedules in infancy to determine the effect of the number of
priming doses and type of vaccine on the number and kinetics of
memory B-cells generated.
Materials and Methods
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1.
Participants and Vaccines
Ethical approval for the study was granted by the Oxfordshire
Research Ethics Committee (study number: OXREC 10/H0604/
7). Participants included in the data reported here were enrolled in
a large open-label randomised controlled trial conducted in four
centres in the UK and one centre in Malta. Children recruited at a
research site with access to the necessary laboratory facilities, who
were able to provide sufficient volumes of blood (.4 mL), and
where samples were able to be processed within 6 hours were
included in the analysis reported here. Previously un-immunised,
healthy term infants aged 6–12 weeks, without evidence of pre-
existing medical conditions were enrolled by study doctors when
written informed consent was obtained from parents or guardian.
Participants were randomised to one of four study groups by
sequentially opening sealed envelopes prepared by an independent
statistician. The ratio of children randomised to each group was
10:10:4:7 respectively for 1-dose MenC-CRM group: 2-dose
MenC-CRM group: 1-dose MenC-TT group: control group.
Randomisation was generated in fixed blocks of 30 using Stata
version 10 (StatCorp LP, Texas, USA). Participants in the 1-dose
MenC-CRM group received MenC-CRM197 (Menjugate Kit,
Novartis Vaccines and Diagnostics, Basel, Switzerland) at 3
months of age; the 2-dose MenC-CRM group received MenC-
CRM197 at 3 and 4 months of age; the 1-dose MenC-TT group
received MenC-TT (Neisvac-C, Baxter Healthcare, Deerfield,
Illinois, USA) at 3 months; the control group did not receive
any primary MenC vaccine doses. All children received a Hib-
MenC-TT (Menitorix, GlaxoSmithKline Biologicals, Rixensart,
Belgium) booster at 12 months of age.
Concomitant vaccines administered according to the routine
UK infant immunisation schedule were: combination diphtheria,
tetanus, acellular pertussis, inactivated poliovirus and Hib vaccine
(Pediacel, Sanofi Pasteur MSD, Lyon, France) at 2, 3 and 4 months;
13 valent pneumococcal conjugate vaccine (Prevenar-13, Wyeth
Vaccines, Pearl River, New York, USA) at 2, 4 and 12 months of
age; and a combined measles, mumps and rubella vaccine at 13
months of age.
Blood sampling
Blood was drawn at 5 months (1 or 2 months after primary
immunisations), 12 months (before Hib-MenC-TT booster) and 13
months of age (1 month post-booster). All children in the control
group, as well as an equal number from each of the other study
groups also had a blood sample drawn 6 days after the 12 month
Hib-MenC-TT booster. Study staff performing blood draws were
not blinded to group assignment as they needed to know which
vaccines to administer to each participant as part of the larger
clinical trial.
Separation of PBMCs by density gradient centrifugation
Heparinised whole blood samples (2–4.5 ml) were processed
within 6 hours of collection. PBMCs were isolated by diluting
blood in R0 ‘‘complete’’ medium and layering over a density
gradient medium (Lymphoprep; Alere, UK) as previously
described by Kelly et al, and Blanchard et al [12,13].
In vitro stimulation of PBMCs for differentiation of
memory B-cells into ASCs
26105 cells/well of isolated PBMCs were seeded into 96-well,
cell culture treated plates (Greiner-One Bio, UK) and stimulated
with 100 ml/well of a mixture of 1:5000 Staphylococcus aureus Cowan
1 strain (SAC Pansorbin cells, Merck-Millipore, UK), 1.7 mg/ml
CpG (BioScience Ltd, UK) and 83.33 ng/ml pokeweed mitogen
(Sigma-Aldrich, UK). This combination induces polyclonal
stimulation of B-cells and maximal proliferation of memory B-
cells allowing differentiation of small antigen-specific populations
into IgG-ASCs that may be detected by ELISpot [14,15]. Plates
were incubated at 37uC, 5% CO2 and 95% humidity for 5–6 days.
Harvested cells were washed in phosphate buffered saline with
ethylenediaminetetraacetic acid (EDTA) di-sodium and 0.5%
newborn bovine serum (Sigma-Aldrich, UK) and re-suspended in
R10 medium to a concentration of 26106 cells/ml.
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Preparation of antigen coated ELISpot plates
96-well multiscreen-IP filter plates with polyvinylidene mem-
branes (Merck-Millipore, UK) were coated with 100 mL the
following antigens: 10 mg/ml goat anti-human Ig (Caltag Medsys-
tems, UK); 10 mg/ml diphtheria toxoid (Staten Seruminstitut,
Denmark); 5 mg/ml tetanus toxoid (Statens Seruminstitut, Den-
mark); or 5 mg/ml MenC polysaccharide mixed with 5 mg/ml
methylated human serum albumin (National Institute for Biolog-
ical Standards and Control [NIBSC], UK). Anti-human Ig,
tetanus and diphtheria toxoids were included as positive controls
and 100 mL phosphate buffered saline (PBS) (pH 7.2–7.4) as
background control.
ELISpot assay for detection of IgG-ASCs
As previously described [12,13], 26105 cells/well cultured
PBMCs and 1:100 and 1:1000 dilutions of Ig controls were added
to the antigen-specific wells and Ig-coated wells respectively. Plates
were incubated at 37uC, 5% CO2 and 95% humidity overnight.
The supernatants were then discarded and the plates were
repeatedly washed with PBS and detergent (0.25% Tween). Plates
were then incubated for 4 hours at room temperature with 50 mL/
well (1:5000) of goat anti-human c-chain-specific alkaline phos-
phatase conjugate (Merck Chemicals Ltd, UK) and then washed
repeatedly in PBS-Tween0.25% and sterile H2O. Spots were
developed using 5-bromo-4-chloro-3-indolyl phosphate in nitro-
blue tetrazolium dissolved in aqueous dimethylformamide pre-
pared from a kit (Bio-Rad Laboratories, UK).
Automated enumeration of IgG-ASC spots
ELISpot plates were scanned and counted using AID ELISpot
reader version 5.0 and verified by visual inspection. Identical
settings were used for all plates and antigens by a blinded operator.
If ,3 well replicates were available and variation was more than
15%, the sample was excluded from analysis for that antigen. For
samples taken from children aged 12 months or older, if the total
IgG spots/million PBMCs was ,1000, the sample was excluded
from analysis. Due to the overall poor immune responses expected
in infants, no exclusion criteria was used on the basis of a positive
control (anti-IgG) response for blood samples drawn from children
at 5 months of age. Other authors have used similar exclusion
criteria when using the ELISpot assay to detect memory B-cells in
blood from children .12 months of age [12,16], but not used such
an exclusion criteria for blood samples drawn from infants ,12
months of age [13].
Statistics
Sample size calculation for the full study was based on the
primary objective to determine non-inferiority of antibody
response following booster vaccination in the 1-dose MenC-
CRM group compared to the 2-dose MenC-CRM group (to be
reported elsewhere). The subset of participants on whom memory
B-cells were measured were selected pragmatically from those
recruited at the Oxford research site, from whom a sufficient blood
volume could be drawn and where the sample could be processed
in time. All comparisons of B-cell responses between study groups
were exploratory. Primary analyses were based on all available
blood samples (intention-to-treat analysis) as pre-specified in the
statistical analysis plan for the randomised controlled trial within
which this study was embedded. Calculations were carried out
using Stata version 12 (StatCorp LP, Texas, USA) and GraphPad
PRISM version 4.00 for Windows (GraphPad Software, San
Diego California, USA, www.graphpad.com).
When no cells were detected in the assay for an antigen, results
were assigned a value of half the lowest level of detection (0.31
cells/million PBMCs) to enable log10 transformation. A one-way
analysis of variance (ANOVA) was conducted of the log10
transformed data to test for differences between groups in the
number of memory B-cells detected at each visit. If the F-test for
groups from the ANOVA was significant, pairs of groups were
compared. Residual variance was checked for normality, and
within-groups variance was tested for heterogeneity (Bartlett’s test).
If the data appeared to be non-normal, non-parametric Kruskal
Wallis analysis was carried out. Comparisons were reported with
95% confidence intervals (CIs) and Bonferroni adjusted p-values
for multiple comparisons.
Linear mixed models were used to estimate mean differences
between two time-points for each group using log10 transformed
data. The mixed model takes account of missing data and the
correlation between measurements on the same child at two time-
points. The fixed effects were: group, time-point and the
interaction between group and time-point. The covariance matrix
was unstructured. The mean difference between two time-points
for each group was estimated using log10 transformed data.
Results
509 children were recruited across all research sites between
July 2010 and July 2011, 404 of whom were recruited from a
single site (Oxford) and included in the analysis presented here.
Memory B-cell results were available from at least one time-point
for 332 children, of whom 149 were female. 200 children had
blood samples available for analysis from at least two time-points.
The median age at first vaccination was 59 days (range 51–102).
There were no significant differences between study groups with
respect to age, gender or ethnicity of participants. 540 blood
samples were available for analysis of memory B-cell responses.
Details of sample inclusions and exclusions are outlined in figure 1.
Figure 2 describes the study timeline with respect to vaccines
administered and blood sampling time-points.
Nine samples, (2 from visit 5, 3 from visit 6 and 4 from visit 7)
were affected by a temporary incubator CO2 regulator failure.
These plates were placed into sealable plastic boxes with CO2
sachets when the failure was discovered, and results included in the
final analysis. The duration of effect on each sample was between
3 to 6 days. One participant randomised to the 1-dose MenC-TT
group received vaccinations according to the 1-dose MenC-CRM
group. Results for this participant were analysed in the 1-dose
MenC-TT group (intention-to-treat analysis). Sample exclusions
and protocol deviations did not disproportionately affect any of the
study groups.
MenC-specific memory B-cells
Figure 3 illustrates all data points available for the number of
MenC memory B-cells/million peripheral blood mononuclear
cells (PBMCs) measured for each participant, according to study
group, at each time-point.
At 5 months of age there were large numbers of samples in
which no antigen-specific memory B-cells could be identified (46%
of observations); the data were not normally distributed and were
not analysed by parametric methods. No statistically significant
difference was seen between children who received 1- or 2-dose
MenC-CRM197 priming at any time-point in the number of
MenC-specific memory B-cells generated (Table 1). Control
children had fewer MenC memory B-cells than all other groups
after the primary vaccines and until 1 month after the booster
(table 1 and Table S1 in file S1). There were no statistically
Immune Memory following Infant MenC Conjugate Vaccination
PLOS ONE | www.plosone.org 3 July 2014 | Volume 9 | Issue 7 | e101672
Figure 1. Number of children enrolled and included in the final analysis for MenC-specific memory B-cells.
doi:10.1371/journal.pone.0101672.g001
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I Invitation letters sent (26307) I 
>I No response, returned to sender, 
or declined to participate (25781) 
'I 
I Agreed to participate (526) I 
I Recruitment I ~I I Excluded (122) 
'I 
Enrolled (404) I 
I 
J, J, J, J, 
I Randomisation I 1-dose MenC- 2-dose MenC- Control 1-dose MenC-
CRM group (131) CRM group (126) group (53) n group (94) 
I Follow-up I Analysis I ~ ~ ~ 
Visit 4 (5 months of age) 
Included 72 71 29 48 
Wrong vaccine administered 0 0 0 1 (MenC-CRM) 
Exclusions: 
Blood sample not available, insufficient 57 52 21 41 
or unable to process 
Withdrawn due to adverse event 0 1 0 0 
Withdrawal of consent 0 2 2 1 
Moved/Lost to follow-up 0 0 0 4 
ELl Spot plate contamination 2 0 1 0 
Visit 5 (12 months of age) 
Included 65 44 27 37 
Temporary C02 regulator failure 1 0 0 1 
Exclusions: 
Blood sample not available, insufficient 61 75 23 42 
or unable to process 
Previous withdrawal 0 3 2 5 
Withdrawal of consent 1 0 1 2 
Moved/Lost to follow-up 3 2 0 4 
Failed positive control 1 2 0 4 
Visit 6 (12 months+ 6 days) 
Randomised for blood sample 52 52 53 55 
Included 23 19 19 15 
Temporary C02 regulator failure 1 2 3 0 
Exclusions: 
Blood sample not available, insufficient 24 28 30 28 
or unable to process 
Previous withdrawal 4 5 3 11 
Withdrawal of consent 1 0 0 0 
Failed positive control 0 0 1 1 
Visit 7 (13 months of age) 
Included 57 50 21 34 
Wrong vaccine administered 0 0 0 1 (MenC-CRM) 
Temporary COz regulator failure 3 1 0 0 
Exclusions: 
Blood sample not available, insufficient 67 69 29 48 
or unable to process 
Previous withdrawal 5 5 3 11 
Withdrawal of consent 2 0 0 1 
Moved/Lost to follow-up 0 2 0 0 
significant differences in the number of MenC memory B-cells
generated one month after the Hib-MenC-TT booster by un-
primed children (control group) and children who had received
either 1 or 2 doses of MenC-CRM197 primary vaccines. By 13
months of age, children in the 1-dose TT group had generated
more MenC-specific memory B-cells than children in either the 1-
dose or 2-dose MenC-CRM groups (table 1).
Using linear mixed models to analyse the log10 transformed
data, a statistically significant rise was seen in the number of
MenC-specific memory B-cells between the pre- and post-booster
blood samples for each study group with a greater rise seen in the
control group and the 1-dose MenC-TT group compared to the 1-
and 2-dose MenC-CRM groups (Table S2 in file S1). P-values are
reported for the comparison of each group mean difference with 0.
Frequencies of MenC-specific memory B-cells
The proportion of MenC-specific memory B-cells out of the
total pool of IgG positive memory B-cells was calculated at each
time-point for all the primed children (pooled samples from 1-dose
MenC-CRM, 2-dose MenC-CRM and 1-dose MenC-TT groups)
as well as for unprimed children in the control group (table 2). The
median proportion of MenC-specific memory B-cells in the
control group was 0% until 1 month after the Hib-MenC-TT
booster. By 13 months of age 0.07% (median) of control children’s
IgG positive memory B-cells were MenC-specific, similar to the
median percentage of MenC-specific memory B-cells in previously
primed children (0.08%).
Differentiating primed and un-primed children
Blood samples drawn 6 days after the Hib-MenC-TT booster
were used to compare primed children (groups 1, 2, and 4) and un-
primed (control) children (Figure 4). A threshold of 2.5 MenC
memory B-cells/million PBMCs was picked by visually inspecting
the data and drawing a line through the point that would best
separate results from the primed compared to the un-primed
children. Use of this ‘‘threshold’’ as a test to detect primed children
gives a sensitivity of 0.86 and specificity of 0.89.
Kinetics of memory B-cell generation
The kinetics of MenC memory B-cell generation over time for
each group is shown in figure 5 based on geometric mean
concentrations calculated for the number of MenC-specific
memory B-cells detected at each time-point for each group. The
kinetics of memory B-cell production for the control antigens,
diphtheria (Dip) and tetanus (Tet) are also included. The patterns
for each group appear to be antigen-specific.
Using linear mixed models of the log10 transformed data, a
statistically significant rise was seen in the number of memory B-
cells between 5 months (1 month after primary vaccines) and 12
months of age (prior to booster vaccines) across all antigens tested
with the exception of MenC-specific memory B-cells in the control
children. P-values for the differences between the 5-month and 12-
month samples (when compared with a difference of 0) are
reported in Table S3 in file S1. To exclude variability in the assay
over time, MenC-specific memory B-cell responses for all children
were plotted according to calendar month of blood sampling for
the 5-month and 12-month samples. No change in the pattern of
results was seen over time (results not included).
Discussion
This is the first study to evaluate serogroup C meningococcal
memory B-cell responses following different priming schedules in
infants with different conjugate vaccines, and has surprisingly
found that priming does not produce a significant improvement in
the memory response to a booster dose of vaccine 7 months later
in comparison to unprimed controls. Furthermore, no evidence
was seen in this study for a relationship between the number of
priming doses of MenC-CRM197, and the generation of MenC-
specific memory B-cells at any time-point following primary or
booster immunisations in infants. These findings are in contrast to
previously published studies which examined immunological
memory after immunisation using antibody responsiveness as a
surrogate and found that antibody responses following a booster
were higher in those who had received fewer priming vaccine
Figure 2. Schedule of study visits and procedures, including vaccines administered and timing of blood draws used to measure
MenC-specific memory B-cells.
doi:10.1371/journal.pone.0101672.g002
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doses. Borrow et al [11] showed that infants primed with 1 dose of
MenC-TT in the first year of life, mounted a greater antibody
response to a polysaccharide challenge at 12 months of age,
compared to priming with either 2 or 3 doses of MenC-TT. A
more recent study has shown that antibody levels following a
MenC-TT booster at 12 months of age are higher in children who
received 1 dose of the same vaccine at 4 months of age, compared
to children who received 2 doses at 2 and 4 months [10]. Similar
results were demonstrated in a study comparing 1, 2 or 3 doses of
pneumococcal conjugate vaccine in infancy, followed by a dose of
pneumococcal polysaccharide vaccine at 12 months of age [17].
Children who had received a single dose of priming vaccine
mounted a greater serotype-specific antibody response following
polysaccharide challenge than children who had received 2 or 3
priming doses. These previous studies imply that limiting the
number of ‘‘priming’’ doses of vaccine may favour memory
formation, at the expense of initial antibody response, potentially
providing longer term protection. The results of the immunoge-
nicity component of the current study confirmed these previous
findings, demonstrating significantly greater MenC SBA titres
following Hib-MenC-TT booster in children previously primed
with a single dose, compared to two priming doses of MenC-
CRM197 [18]. However, with very small numbers of memory B-
cells detected before booster vaccination, the current study may
have lacked power to detect a difference between 1- and 2-dose
priming with MenC-CRM197 conjugate vaccine with respect to
memory B-cell responses.
It is not clear what signals are required to determine memory B-
cell production following activation of naı¨ve B-cells. It has been
suggested that a population of naı¨ve B-cells are intrinsically able to
commit to any fate based on stochastic factors influenced by a
large number of external and intrinsic signals [19,20]. Some of
these signals may favour differentiation into plasma cells over
memory cells, or vice versa, and may include the type or amount
Figure 3. Number of MenC-specific memory B-cells (log10 scale) detected in the peripheral blood of individual participants after
immunisation with different schedules of MenC conjugate vaccines, at each time-point following infant primary and booster
vaccines.
doi:10.1371/journal.pone.0101672.g003
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of antigen used for immunization [21]. In the current study, the
number of MenC-specific memory B-cells detected by the ELISpot
assay was shown to be related to the type of vaccine used for
priming and boosting. Whether these differences are related to the
carrier proteins used in these vaccines, or other compositional
differences is uncertain. Children primed with MenC-TT conju-
gate vaccine generated more memory B-cells following a Hib-
MenC-TT booster than children previously primed with MenC-
CRM197, suggesting that the carrier protein used for priming and
boosting may have an important role in determining the
polysaccharide-specific response to conjugate vaccines. These
data may provide indirect evidence to support the recent finding
from murine studies that an association of peptides from the
carrier protein, along with oligosaccharides from the sugar
component of conjugate vaccines, are presented together to T-
cells on major histocompatibility complex (MHC)-II receptors,
challenging the traditional dogma about the mechanism of
immune induction by conjugate vaccines [22]. The structure of
the MenC-CRM197 polysaccharide-conjugate vaccine may inter-
fere with antigen processing and/or presentation on MHC-II
molecules following immunisation, whereas that of the MenC-TT
conjugate vaccine may promote optimal presentation of carbohy-
drate epitopes recognised by T-cells. If this mechanism is verified
in humans, it has important implications for new generation
conjugate vaccine development.
The differences between vaccines in induction of MenC-specific
memory B-cells may explain the differential antibody response
noted following primary and booster vaccines when children were
primed with either a MenC-CRM197 vaccine or Hib-MenC-TT in
the first year of life and given a Hib-MenC-TT booster as toddlers
Table 1. Comparison between groups of the log10 transformed number of MenC-specific memory B-cells detected in the
peripheral blood at each visit.
Kruskal-Wallis statistic p-value
5 months of age (1 or 2 months after primary vaccines)
Between groups 1-dose CRM, 2-dose CRM, and 1-dose TT X22 = 4.9 0.09
Groups 1-dose CRM, 2-dose CRM, 1-dose TT vs control* X21 = 10.2 0.001
F test and unadjusted p-value Difference between groups
with estimated 95% CI
Bonferroni adjusted p-value
12 months of age (pre-booster)
Between groups 1-dose CRM, 2-dose
CRM, and 1-dose TT
F2, 169 = 1.4, p = 0.24
Groups 1-dose CRM, 2-dose
CRM, 1-dose TT vs control*
F1, 169 = 16.6, p=0.0001
12 months +6 days (6 days after booster vaccination)
Between groups 1-dose CRM, 2-dose
CRM, and 1-dose TT
F2, 72 = 1.2, p = 0.3
Groups 1-dose CRM, 2-dose
CRM, 1-dose TT vs control*
F1, 72 = 49.9, p,0.0001
13 months of age (1 month after booster vaccination)
1-dose CRM vs control F1, 158 = 0.4, p = 0.51 20.10 (20.41 to 0.21) 1.0
2-dose CRM vs control F1, 158 = 1.4, p = 0.25 20.19 (20.50 to 0.13) 1.0
1-dose TT vs control F1, 158 = 6.0, p = 0.02 0.42 (0.08 to 0.765) 0.09
1-dose CRM vs 2-dose CRM F1, 158 = 0.5, p = 0.5 0.08 (20.15 to 20.32) 1.0
1-dose CRM vs 1-dose TT F1, 158 = 15.2, p = 0.0001 20.52 (20.78 to 20.26) 0.001
2-dose CRM vs 1-dose TT F1, 158 = 19.5, p,0.00001 20.60 (20.87 to 20.33) ,0.0001
1-dose CRM: 1 dose MenC-CRM197 at 3 months of age; 2-dose CRM: 2 doses of MenC-CRM197 at 3 and 4 months of age; Control: No MenC primary vaccine doses; 1-dose
TT: 1 dose MenC-TT at 3 months of age.
*Results of the analysis of pairs of groups are provided in Table S1 in file S1.
doi:10.1371/journal.pone.0101672.t001
Table 2. Proportion of MenC-specific memory B-cells out of the total pool of IgG positive memory B-cells detected in the
peripheral blood at each time-point.
5 months of age 12 months of age 6 days after 12-month booster 13 months of age
Primed children Median 0.02% 0.04% 0.12% 0.08%
IQR 0%–0.097% 0.013%–0.094% 0.054%–0.22% 0.033%–0.23%
Unprimed children (Control group) Median 0.0% 0.0% 0.0% 0.07%
IQR 0%–0.016% 0%–0.022% 0%–0.019% 0.029%–0.20%
IQR: Interquartile range.
doi:10.1371/journal.pone.0101672.t002
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[8,9]. In these earlier studies, children in the MenC-CRM197
primed groups had higher SBA titres one month after primary
vaccines, but lower SBA titres one month after the Hib-MenC-TT
booster, than children in the Hib-MenC-TT primed groups.
Similarly, children primed with MenC-TT have been shown to
mount a greater SBA response following either MenC-TT or
MenC-CRM197 booster in the second year of life, than children
primed with MenC-CRM197 [7]. These observations may be
related to a greater number of MenC memory B-cells generated by
Hib-MenC-TT and MenC-TT than by MenC-CRM197 primary
immunisations. Although in the current study no statistically
significant difference was seen in the number of memory B-cells at
5 months of age in children who had received either MenC-TT or
MenC-CRM197 at 3 months of age, there was a trend towards
higher numbers in the MenC-TT group (data not presented).
In the absence of immunisation programmes, adolescents and
young adults have a high incidence of invasive meningococcal
disease and high case fatality rate (10–14%) compared to younger
children and to adults, and are also the drivers for transmission of
the organism through high nasopharyngeal carriage rates (10–
35%) [23]. The only validated correlate of protection against
invasive MenC disease is an SBA titre $1:8 using rabbit
complement or $1:4 using human complement [1,2,3]. Thus
persistence of bactericidal antibody beyond childhood is critical for
both direct protection of individuals through the ‘‘high risk’’
period of adolescence, and for maintenance of herd immunity.
The level of MenC-specific memory B-cells produced after
priming vaccines has been shown to correlate with the persistence
of antibody and memory B-cells at one year of age, and with post-
booster antibody and memory B-cell levels [12]. In addition, the
persistence of MenC bactericidal antibody through early child-
hood is greater in children who mount a greater response to the
toddler booster dose of vaccine [24]. Thus, vaccines which induce
more memory B-cells following primary and booster immunisa-
tions may be associated with greater persistence of bactericidal
antibody throughout childhood and adolescence and offer a
practical advantage for infant immunisation schedules.
In this study, a rise in antigen-specific memory B-cells was seen
following primary immunisations until booster vaccination at 12
months of age for all antigens tested. Variability in the assay over
time was excluded and for MenC, this finding was consistent with
an increase in the proportion of MenC-specific memory B-cells out
of the total pool of IgG positive memory B-cells from 0.02% at 5
months to 0.04% at 12 months of age, suggesting that this is an
antigen-specific increase, rather than a non-specific effect of
immune maturation in infants. Furthermore, the absence of a rise
in the number of MenC-specific memory B-cells in unprimed
children suggests that this a true effect of priming on memory B-
cell production. However, the rise in antigen-specific memory B-
cells in this study is in contradiction to the findings of Blanchard et
al who noted a decline in MenC memory B-cells between 5 and 12
months of age following 3 doses of MenC-CRM197 at 2, 3 and 4
months of age [12]. The main difference between these two studies
is in the number of memory B-cells detected at 5 months of age:
median 0.1–0.8 per million PBMCs in children primed with
MenC-CRM197 in the current study versus 11 per million PBMCs
in the Blanchard et al trial. This may be related to the number of
primary doses of vaccine administered (1 or 2 in the current study
versus 3 in the previous trial). Furthermore, Blanchard et al used
different concentrations of SAC and CpG which may have led to
greater B-cell stimulation and higher spot counts in general. The
differences are unlikely to be related to changes in carriage rates of
Figure 4. Number of MenC-specific memory B-cells detected in the peripheral blood of infants 6 days after a Hib-MenC-TT booster
at 12 months of age, according to different primary immunisation schedules (magnified from Figure 3).
doi:10.1371/journal.pone.0101672.g004
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Figure 5. Kinetics of the number of antigen-specific memory B-cells detected in the peripheral blood of infants after immunisation
with different schedules of MenC conjugate vaccines, at each time-point following primary and booster vaccines, based on
geometric mean concentrations for each study group at each visit.
doi:10.1371/journal.pone.0101672.g005
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MenC in the UK between 2005 and 2011/2012, since even prior
to the introduction of MenC conjugate vaccines only 0.45% of
adolescents were colonised with MenC, and this had reduced to
0.15% by 2000 [4], with carriage rates in infants being virtually
zero.
The formation of new memory B-cells for several months after
immunisation suggests that this may either be occurring indepen-
dent of the germinal centre (GC), or alternatively, in these infants,
the GC reaction may continue for longer than is traditionally
understood. The memory B-cell population in humans and higher
vertebrates is known to be heterogeneous [21]. In mice, antigen-
specific B-cells with a memory phenotype have been demonstrated
early in a GC reaction, with evidence of stable numbers or
continued output for at least 5 weeks [25]. In addition, studies in
mice indicate that GC-independent memory B-cells can be formed
[26,27] and subsets of memory B-cells continue to proliferate in
GC-like structures in splenic B-cell follicles for up to 8 months after
immunization [28]. In humans, memory B-cells have been shown
to continue to proliferate and differentiate into plasma cells in
lymphoid tissues for several months after immunisation in response
to antigen persisting on follicular dendritic cells [29]. In line with
the mouse models described above, our results suggest that
memory B-cells can continue to be generated for months beyond
the original antigen stimulation.
In the context of waning bactericidal antibody described in the
first year of life following infant immunizations [8,30], an increase
in the number of MenC-specific memory B-cells between 5 and 12
months of age suggests that after primary MenC vaccines, memory
B-cells continue to be generated for several months, but there is a
decline in the proportion that differentiate into plasma cells.
Despite waning of bactericidal antibody levels, antibody avidity
has also been shown to increase following primary immunisations
with MenC and pneumococcal conjugate vaccines in infants, until
12 months of age [11,31]. One explanation for the discordance in
antibody levels (waning over time) and antibody avidity and
memory B-cell numbers (increasing over time) may be that
separate B-cell precursors are responsible for the primary
antibody-producing and memory B-cell populations [32]. It
should be noted however, that as no blood samples were drawn
in this study between 5 and 12 months of age, we cannot exclude a
higher peak in memory B-cell numbers at an earlier time-point
after 5 months, with a decline until 12 months of age.
Primary and secondary GC reactions have been shown to be
qualitatively very similar [33] although there are several quanti-
tative differences, including the speed with which they develop.
During a secondary response, IgG memory B-cells appear in the
circulation more rapidly, and in adolescents receiving a booster
dose of MenC conjugate vaccine memory B-cells were detected by
day 6 [34]. For a tetanus booster in adults an increase in memory
B-cells was not seen by day 4 but by day 12 there was a significant
rise [14]. In infants, after the third dose of vaccine antigen-specific
memory B-cells were readily detectable at all time-points from day
4 to 30 [13]. Most clinical vaccine trials compare pre- and post-
booster antibody levels to detect an anamnestic response; often
one month apart and based on a polysaccharide vaccine
‘‘challenge’’. In the current study, detection of at least 2.5 MenC
memory B-cells/million PBMCs in the peripheral blood, 6 days
after a booster dose of Hib-MenC-TT was able to differentiate
MenC-primed from un-primed children with a sensitivity and
specificity of .85%. This could potentially be used as a novel way
to test the ability of MenC conjugate vaccines to induce immune
memory in infants and young children with the following
advantages: 1) results are available from a single blood test, 2)
earlier time-point to achieve results, 3) avoids the need for
administration of a polysaccharide vaccine as a ‘challenge’ dose in
this population where there are concerns about possible induction
of immunological hypo-responsiveness [35]. This finding needs to
be validated by testing in blinded fashion in other cohorts of
children, as well as with other conjugate vaccines; however this
study provides a ‘‘proof of principle’’ for using the ELISpot assay
for detecting antigen-specific memory B-cells on the 6 -day post-
booster blood sample to identify previously ‘‘primed’’ individuals.
Conclusions
MenC-specific memory B-cell production may be more
dependent on the type of vaccine used for primary immunisation
of infants, and perhaps the matching of carrier proteins, than the
number of doses administered. Although the mechanistic differ-
ences between MenC-CRM197 and MenC-TT priming are
unclear, it is possible that structural differences in these vaccines
may underlie differential interactions with B- and T-cell popula-
tions and thus different effects on various memory B-cell subsets.
The differences between these vaccines in induction of MenC-
specific memory B-cells may explain the differential antibody
response noted following primary and post Hib-MenC-TT booster
immunisations. The MenC-TT/Hib-MenC-TT combination of
vaccines may offer a practical advantage for infant immunisation
schedules in terms of long-term persistence of antibody. Irrespec-
tive of the priming vaccine received, MenC primed children can
be separated from unprimed children with a sensitivity and
specificity of .85% by the detection of at least 2.5 MenC memory
B-cells/million PBMCs in the peripheral blood, 6 days after a Hib-
MenC-TT booster vaccine.
Supporting Information
Checklist S1 CONSORT Checklist.
(DOC)
Protocol S1 Clinical Study Protocol.
(DOC)
File S1 Supplemental data tables: Table S1: Comparison
of the log10 transformed number of MenC-specific memory B-cells
detected in the peripheral blood for each study group against the
control group at visits 4, 5 and 6 (5 months, 12 months and 12
months +6 days). Table S2: Differences in log10 transformed
number of MenC-specific memory B-cells detected in the
peripheral blood between 13-month and 12-month samples for
each study group. Table S3: Differences in the log10 transformed
number of antigen-specific memory B-cells detected in the




The authors would like to acknowledge the contributions of the research
fellows, nurses and support staff who were involved in this study at the
Oxford Vaccine Group. In particular we would like to thank Emma Plested
who helped to co-ordinate the trial; Irene Noel and Danielle Campbell who
worked as research nurses; and Jaclyn Bowman who processed many of the
lab samples. We would also like to thank all of the participants in these
studies and their family members. Finally, thanks to Dr Dominic Kelly for
his advice during the analysis of the results.
Author Contributions
Conceived and designed the experiments: AK EAC DP MDS AJP.
Performed the experiments: AK EAC AJT JAM. Analyzed the data: AK
JB. Wrote the paper: AK EAC AJT JAM DP JB MDS AJP.
Immune Memory following Infant MenC Conjugate Vaccination
PLOS ONE | www.plosone.org 10 July 2014 | Volume 9 | Issue 7 | e101672
References
1. Campbell H, Andrews N, Borrow R, Trotter C, Miller E (2010) Updated
postlicensure surveillance of the meningococcal C conjugate vaccine in England
and Wales: effectiveness, validation of serological correlates of protection, and
modeling predictions of the duration of herd immunity. Clin Vaccine Immunol
17: 840–847.
2. Borrow R, Balmer P, Miller E (2005) Meningococcal surrogates of protection–
serum bactericidal antibody activity. Vaccine 23: 2222–2227.
3. Andrews N, Borrow R, Miller E (2003) Validation of serological correlate of
protection for meningococcal C conjugate vaccine by using efficacy estimates
from postlicensure surveillance in England. Clin Diagn Lab Immunol 10: 780–
786.
4. Maiden MC, Stuart JM (2002) Carriage of serogroup C meningococci 1 year
after meningococcal C conjugate polysaccharide vaccination. Lancet 359: 1829–
1831.
5. Trotter CL, Andrews NJ, Kaczmarski EB, Miller E, Ramsay ME (2004)
Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after
introduction. Lancet 364: 365–367.
6. Richmond P, Borrow R, Goldblatt D, Findlow J, Martin S, et al. (2001) Ability
of 3 different meningococcal C conjugate vaccines to induce immunologic
memory after a single dose in UK toddlers. J Infect Dis 183: 160–163.
7. Diez-Domingo J, Cantarino MV, Torrenti JM, Sansano MI, Rosich AJ, et al.
(2010) A randomized, multicenter, open-label clinical trial to assess the
immunogenicity of a meningococcal C vaccine booster dose administered to
children aged 14 to 18 months. Pediatr Infect Dis J 29: 148–152.
8. Pace D, Snape M, Westcar S, Oluwalana C, Yu LM, et al. (2008) A novel
combined Hib-MenC-TT glycoconjugate vaccine as a booster dose for toddlers:
a phase 3 open randomised controlled trial. Arch Dis Child 93: 963–970.
9. Khatami A, Snape MD, Ohene-Kena B, Young K, Oeser C, et al. (2013) Phase
II Study of a Three-Dose Primary Vaccination Course of DTPa-IPV/Hib-
MenC-TT Followed by a 12-Month Hib-MenC-TT Booster in Healthy Infants.
Pediatr Infect Dis J.
10. Poellabauer EM, Pavlova BG, Fritsch S, Singer J, Neubauer C, et al. (2013)
Single priming dose of meningococcal group C conjugate vaccine (NeisVac-
C((R))) in infants. Vaccine 31: 3611–3616.
11. Borrow R, Goldblatt D, Finn A, Southern J, Ashton L, et al. (2003)
Immunogenicity of, and immunologic memory to, a reduced primary schedule
of meningococcal C-tetanus toxoid conjugate vaccine in infants in the United
kingdom. Infect Immun 71: 5549–5555.
12. Blanchard Rohner G, Snape MD, Kelly DF, John T, Morant A, et al. (2008)
The magnitude of the antibody and memory B cell responses during priming
with a protein-polysaccharide conjugate vaccine in human infants is associated
with the persistence of antibody and the intensity of booster response. J Immunol
180: 2165–2173.
13. Kelly DF, Snape MD, Perrett KP, Clutterbuck EA, Lewis S, et al. (2009) Plasma
and memory B-cell kinetics in infants following a primary schedule of CRM 197-
conjugated serogroup C meningococcal polysaccharide vaccine. Immunology
127: 134–143.
14. Nanan R, Heinrich D, Frosch M, Kreth HW (2001) Acute and long-term effects
of booster immunisation on frequencies of antigen-specific memory B-
lymphocytes. Vaccine 20: 498–504.
15. Maurer D, Fischer GF, Fae I, Majdic O, Stuhlmeier K, et al. (1992) IgM and
IgG but not cytokine secretion is restricted to the CD27+ B lymphocyte subset.
J Immunol 148: 3700–3705.
16. Clutterbuck EA, Oh S, Hamaluba M, Westcar S, Beverley PC, et al. (2008)
Serotype-specific and age-dependent generation of pneumococcal polysaccha-
ride-specific memory B-cell and antibody responses to immunization with a
pneumococcal conjugate vaccine. Clinical and vaccine immunology: CVI 15:
182–193.
17. Russell FM, Licciardi PV, Balloch A, Biaukula V, Tikoduadua L, et al. (2010)
Safety and immunogenicity of the 23-valent pneumococcal polysaccharide
vaccine at 12 months of age, following one, two, or three doses of the 7-valent
pneumococcal conjugate vaccine in infancy. Vaccine 28: 3086–3094.
18. Pace D, Khatami A, McKenna J, Campbell D, Attard-Montalto S, et al. (2013)
Immunogenicity of a conjugate meningococcal serogroup C booster dose
following a reduced vaccination schedule in infancy. European Society of
Pediatric Infectious Diseases. Milan, Italy.
19. Hawkins ED, Turner ML, Dowling MR, van Gend C, Hodgkin PD (2007) A
model of immune regulation as a consequence of randomized lymphocyte
division and death times. Proc Natl Acad Sci U S A 104: 5032–5037.
20. Hodgkin PD (2005) Quantitative rules for lymphocyte regulation: the cellular
calculus and decisions between tolerance and activation. Tissue Antigens 66:
259–266.
21. Good-Jacobson KL, Shlomchik MJ (2010) Plasticity and heterogeneity in the
generation of memory B cells and long-lived plasma cells: the influence of
germinal center interactions and dynamics. J Immunol 185: 3117–3125.
22. Avci FY, Li X, Tsuji M, Kasper DL (2011) A mechanism for glycoconjugate
vaccine activation of the adaptive immune system and its implications for
vaccine design. Nat Med 17: 1602–1609.
23. Caugant DA, Tzanakaki G, Kriz P (2007) Lessons from meningococcal carriage
studies. FEMS Microbiol Rev 31: 52–63.
24. Khatami A, Snape MD, John T, Westcar S, Klinger C, et al. (2011) Persistence
of Immunity Following a Booster Dose of Haemophilus Influenzae Type B-
Meningococcal Serogroup C Glycoconjugate Vaccine: Follow-up of a
Randomized Controlled Trial. Pediatr Infect Dis J 30: 197–202.
25. Blink EJ, Light A, Kallies A, Nutt SL, Hodgkin PD, et al. (2005) Early
appearance of germinal center-derived memory B cells and plasma cells in blood
after primary immunization. J Exp Med 201: 545–554.
26. Obukhanych TV, Nussenzweig MC (2006) T-independent type II immune
responses generate memory B cells. J Exp Med 203: 305–310.
27. Alugupalli KR, Leong JM, Woodland RT, Muramatsu M, Honjo T, et al. (2004)
B1b lymphocytes confer T cell-independent long-lasting immunity. Immunity
21: 379–390.
28. Dogan I, Bertocci B, Vilmont V, Delbos F, Megret J, et al. (2009) Multiple layers
of B cell memory with different effector functions. Nat Immunol 10: 1292–1299.
29. Holder MJ, Abbot SD, Milner AE, Gregory CD, Casamayor M, et al. (1993) IL-
2 expands and maintains IgM plasmablasts from a CD5+ subset contained
within the germinal centre cell-enriched (surface IgD-/CD39- buoyant) fraction
of human tonsil. Int Immunol 5: 1059–1066.
30. Campbell H, Borrow R, Salisbury D, Miller E (2009) Meningococcal C
conjugate vaccine: the experience in England and Wales. Vaccine 27 Suppl 2:
B20–29.
31. Goldblatt D, Southern J, Ashton L, Richmond P, Burbidge P, et al. (2006)
Immunogenicity and boosting after a reduced number of doses of a
pneumococcal conjugate vaccine in infants and toddlers. Pediatr Infect Dis J
25: 312–319.
32. Berek C (1992) The development of B cells and the B-cell repertoire in the
microenvironment of the germinal center. Immunol Rev 126: 5–19.
33. Vora KA, Tumas-Brundage K, Manser T (1999) Contrasting the in situ
behavior of a memory B cell clone during primary and secondary immune
responses. J Immunol 163: 4315–4327.
34. Kelly DF, Snape MD, Clutterbuck EA, Green S, Snowden C, et al. (2006)
CRM197-conjugated serogroup C meningococcal capsular polysaccharide, but
not the native polysaccharide, induces persistent antigen-specific memory B cells.
Blood 108: 2642–2647.
35. Granoff DM, Pollard AJ (2007) Reconsideration of the use of meningococcal
polysaccharide vaccine. The Pediatric infectious disease journal 26: 716–722.
Immune Memory following Infant MenC Conjugate Vaccination
PLOS ONE | www.plosone.org 11 July 2014 | Volume 9 | Issue 7 | e101672
